𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Suppression of myoclonus in SCA2 by piracetam

✍ Scribed by Anna De Rosa; Pasquale Striano; Fabrizio Barbieri; Arturo De Falco; Carlo Rinaldi; Tecla Tucci; Salvatore Striano; Alessandro Filla; Giuseppe De Michele

Book ID
102507691
Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
52 KB
Volume
21
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

We report on a 30‐year‐old patient with advanced cerebellar degeneration due to SCA2. He presented with severe myoclonus, which was resistant to conventional therapy and dramatically improved after administration of 12–18 gm/die piracetam. Piracetam may be considered in the treatment of refractory myoclonus in spinocerebellar degenerations. Β© 2005 Movement Disorder Society

πŸ“œ SIMILAR VOLUMES

Effectiveness of piracetam in cortical m
Effectiveness of piracetam in cortical myoclonus
✍ P. Brown; M. J. Steiger; P. D. Thompson; J. C. Rothwell; B. L. Day; M. Salama; T πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 517 KB

## Abstract Twenty‐one patients with disabling spontaneous, reflex, or action myoclonus due to various causes, who had shown apparent clinical improvement on introduction of piracetam, entered a placebo‐controlled double‐blind crossover trial of piracetam (2.4– 16.8 g daily). All but one patient ha

Clinical trial of piracetam in patients
Clinical trial of piracetam in patients with myoclonus: Nationwide multiinstitution study in Japan
✍ Dr. Akio Ikeda; Hiroshi Shibasaki; Kunio Tasgiro; Yoshikuni Mizuno; Jun Kimura πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 1024 KB

## Abstract Sixty patients with disabling myoclonus excluding mainly spinal myoclonus were treated by piracetam as an open‐labeled study, and myoclonus score, neurological symptoms, functional disbility, and intensity of myoclonus were scored before and after treatment, including a blinded video in